Clinical study of a survivin long peptide vaccine (SurVaxM) in patients with recurrent malignant glioma

• DOI: 10.1007/s00262-016-1890-x
• Publication Date: 2016-08-30T08:25:51Z
• Authors: Robert A. Fenster...; Michael J. Ciesie...; Jingxin Qiu; Nuo Yang; Cheryl L. Frank; Kelvin P. Lee; Laszlo R. Mechtler; Ahmed Belal; Manmeet S. Ahluwalia; Alan D. Hutson
• Keywords: Survivin; Peptide vaccine

Survivin is an anti-apoptotic protein that highly expressed in many cancers, including malignant gliomas. Preclinical studies established the conjugated survivin peptide mimic SurVaxM (SVN53-67/M57-KLH) could stimulate anti-tumor immune response against murine glioma vivo, as well human cells ex vivo. The current clinical study was conducted to test safety, immunogenicity and effects of vaccine. Recurrent patients whose tumors were survivin-positive, who had either HLA-A*02 or HLA-A*03 MHC class I allele-positivity, given subcutaneous injections (500 μg) Montanide ISA 51 with sargramostim (100 at 2-week intervals. tolerated mostly grade one adverse events (AE) no serious (SAE) attributable drug. Six experienced local injection site reactions; three reported fatigue (grades 1 2), 2 myalgia (grade 1). eight immunologically evaluable developed both cellular humoral responses vaccine also stimulated HLA-A*02, HLA-A*24 restricted T cell responses. Three maintained a partial stable disease for more than 6 months. Median progression-free survival 17.6 weeks, median overall 86.6 weeks from entry seven nine surviving 12